Pancreatic cancer (PaC) is one of the most aggressive and highly lethal solid malignancies, with a 5-year survival of only 5%. Treatment of PaC is largely dependent on tumor size and location. Surgical resection, and/or chemoradiotherapy/chemotherapy are the most commonly used type of treatments in this solid malignancy.
Using primary research conducted with U.S., and European PaC medical oncologists, who have expertise treating PaC, this report provides a comprehensive analysis of the competitive landscape and market opportunity for PaC. This includes an analysis of patient populations, current therapies and medical practices, unmet needs, and emerging therapies. Of the current therapies used to treat PaC, erlotinib (Roche/Astellas’s Tarceva), is currently the only targeted agent to gain regulatory approval in combination with chemotherapy in this indication. Nab-paclitaxel (Celgene’s Abraxane), a chemotherapy agent used in combination with gemcitabine is the latest and most commonly used addition to the PaC treatment armamentarium.